semaglutide rebound Stopping GLP-1 Weight Loss Drugs Leads to Fast in Weight and Heart Risks, Study Warns Rebound: Stopping anti-obesity drugs leads

They are generally well tolerated when used as directed under medical supervision, but understanding the potential risks is an important part of the evaluation process

Gastrointestinal side effects are the most common issues with GLP-1 receptor agonists, affecting up to 4050% of patients

The market growth is driven by the increasing prevalence of type 2 diabetes and obesity, rising aging population and lifestyle changes, and ongoing development of new and improved drug formulations

1 RELATED: Paleo-Friendly Foods That Support GLP-1 Activity While these drugs were initially developed to treat type 2 diabetes, they are now also prescribed for people with metabolic dysfyunction 2 or obesity, 3 and some people are turning to them for general weight loss